Evidence map›Paper›PMID 40751025›Full record

ArticleJournal of nephrology2025

Intermediate and long-term AKI outcomes in a public health system.

Ana Muñoz-Sánchez, Leyre Martín-Rodríguez, Paula López-Sánchez, Maria Valdenebro, Maria Luisa Serrano-Salazar, Maria Marques, Jose Portoles

Abstract read
In one paragraph

Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Muñoz-Sánchez *Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain.ORCID http://orcid.org/0000-0003-2324-7594
Leyre Martín-Rodríguez *Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain.ORCID http://orcid.org/0000-0001-5854-0577
Paula López-SánchezHospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain.ORCID http://orcid.org/0000-0002-4332-5759
Maria ValdenebroHospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain.ORCID http://orcid.org/0000-0001-5267-6844
Maria Luisa Serrano-SalazarHospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain.ORCID http://orcid.org/0000-0002-6230-6377
Maria MarquesHospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain.ORCID http://orcid.org/0000-0001-9691-2546
Jose PortolesHospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, C/Manuel de Falla S/N, Majadahonda, 28222, Madrid, Spain. josem.portoles@salud.madrid.org.ORCID http://orcid.org/0000-0002-2114-1385

Funding

Instituto de Salud Carlos III PI23/01518Instituto de Salud Carlos III RD24/0004/0028
6 · The paper itself

Abstract

backgroundAcute Kidney Injury (AKI) is frequent and is associated with adverse outcomes.

aimsTo analyze the impact of community-acquired and hospital-acquired AKI on in-hospital and five-year post-discharge kidney replacement therapy (KRT) requirement in the pre-COVID era.

methodsWe linked the regional health system database of 419,851 admissions to the regional KRT registry. We grouped all admissions into 3 categories: community-acquired AKI, where AKI was the primary diagnosis, and hospital-acquired AKI, where AKI was an additional diagnosis alongside another primary condition. Admissions without this code were grouped into a third category (no AKI). We excluded patients aged under 18 years old, those with previous KRT, and pregnant women. The study was approved by the ethics committee. Patients were followed up for five years after discharge.

resultsCommunity-acquired AKI accounted for 0.6% of all admissions, associated prolonged average hospital stays, and increased mortality rates. In-hospital KRT administration was required in 3.1% of cases, and after a mean follow-up time of 459 days, 7.2% of these patients began chronic KRT. Hospital-acquired AKI represented 6.1% of all admissions and was associated with the highest mortality rate (22.9% vs 14.4% in the community-acquired AKI group) and the longest average hospital stay (12.6 days vs 7.1 in the no AKI group). Only 0.5% of hospital-acquired AKI cases required KRT during the AKI episode, while 2% of these patients initiated chronic KRT after a mean follow-up time of 594 days.

conclusionsAKI continues to be a frequent problem in clinical practice, negatively influencing patient morbidity and mortality, and increasing the risk of starting KRT in the medium-long term.

Indexed as

Acute Kidney InjuryRenal Replacement TherapyAdultAgedAged, 80 and overFemaleHospitalizationHospital MortalityHumansLength of StayMaleMiddle AgedRegistriesTime FactorsTreatment OutcomeAcute kidney injuryChronic kidney diseaseDialysisKidney replacement therapyMortality

Identifiers

PMID40751025
PMCPMC12484351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.